Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer
Research output: Contribution to journal › Journal article › Research › peer-review
To evaluate the effect of bicalutamide ('Casodex') 150mg (in addition to standard care), on the risk of prostate-specific antigen (PSA) progression, in patients with early prostate cancer.
| Original language | English |
|---|---|
| Journal | European Urology |
| Volume | 44 |
| Issue number | 5 |
| Pages (from-to) | 512-7; discussion 517-8 |
| ISSN | 0302-2838 |
| Publication status | Published - 2003 |
ID: 48471052